Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of Rademikibart (CBP-201) Dosage Forms in Healthy Chinese Adults
NCT05917782Phase 1Completed
- Sponsor
- Connect Biopharma
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rademikibart in atopic dermatitis (AD) and asthma (3 arms), sponsored by Connect Biopharma. Primary endpoints: Maximum concentration at Day 57, Area under the plasma concentration-time curve from time zero to last measurable concentration at Day 57 and 1 more. Started Jul 2023; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT05917782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917782.